Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke.
Pol Arch Med Wewn. 2016 Oct 28;126(10):803-805
Authors: Gerstein H, Jaeschke R
PMID: 27872459 [PubMed - in process]
Source: Polskie Archiwum Medycyny Wewnetrznej - Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance